anamorecabtagene autoleucel

**Anamorecabtagene autoleucel** is an investigational autologous CAR-T cell therapy developed by an undisclosed company, featuring genetically modified patient-derived T cells engineered with a chimeric antigen receptor targeting BCMA. It utilizes a novel synthetic protein binding domain (non-scFv) as part of an Antigen Receptor Complex-T (ARC-T) platform to selectively kill BCMA-expressing tumor cells, primarily in relapsed or refractory multiple myeloma. Administered intravenously following lymphodepleting chemotherapy, it has demonstrated promising efficacy in early clinical data with high response rates, though specific trial results for this exact agent are limited in available sources.